Article: PATIENTS, SCIENTISTS PERSEVERE IN GETTING ACTIVASE ON MARKET

It's a long, long step from discovery to market for scientists who spend their working lives in the search for safe and effective pharmaceutical products. More often than not, it's one long step after another.

The development of Activase, a registered thrombolytic agent now used in the early treatment of heart attacks, is a fascinating case history.

When administered intraveneously, thrombolytic agents dissolve blood clots, thus halting or diminishing the severity of heart attacks. The earlier it's given, the more likely it is the patient will survive.

First, it's important to recognize the scope of the problems facing cardiologists and other physicians who intervene at various ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!